Zepbound tirzepatide

Zepbound's list price is roughly $1,060 per 28-day supply at retail pharmacies. Eli Lilly runs LillyDirect Self-Pay, which offers vials at $349-$549/month depending on dose for eligible self-pay patients. Pen injectors are not part of the discounted self-pay program — only the single-dose vials. Commercial insurance coverage exists but typically requires prior authorization and meeting BMI thresholds. Lilly's commercial savings card can bring eligible commercial-insured patients to as low as $25/month for the first 6 months, then up to $150/month for the next 6.

Like Wegovy, Zepbound coverage depends on your plan. Many commercial plans require BMI ≥30 (or ≥27 with a comorbidity) and prior authorization. Medicare does not cover Zepbound for weight loss, though it does cover Mounjaro (same active ingredient) for type 2 diabetes. Medicaid coverage varies by state. The Lilly commercial savings card can layer on top of insurance for eligible patients, reducing copay significantly.

At list price, Zepbound is slightly cheaper than Wegovy (~$1,060 vs ~$1,349/month). For cash-pay patients, Lilly's self-pay vial program ($349-$549/month for Zepbound) tends to undercut Novo's NovoCare self-pay program ($499/month for Wegovy) at lower doses. At higher Zepbound doses, the gap narrows. Insurance coverage patterns are similar; the better choice for any individual depends on which drug their formulary covers preferentially.

Medicare currently covers GLP-1 medications only when prescribed for FDA-approved indications other than weight loss. Ozempic, Mounjaro, and Trulicity are covered for type 2 diabetes when medically indicated. Wegovy and Zepbound — both FDA-approved specifically for chronic weight management — are not covered by Medicare. The Treat and Reduce Obesity Act has been introduced in Congress to change this, but as of 2026 it has not become law. Medicare Advantage plans sometimes offer expanded coverage; check your specific plan documents. Medicaid coverage varies significantly by state.

GLP-1 receptor agonists mimic glucagon-like peptide-1, a gut hormone released after eating. They work through three main pathways: (1) Slowing gastric emptying — food stays in the stomach longer, prolonging fullness. (2) Suppressing appetite in the brain — they reduce the constant 'food noise' many patients describe, making it easier to eat smaller portions and skip snacks. (3) Improving insulin response — they enhance glucose-dependent insulin release, which helps with blood sugar control. Tirzepatide (Mounjaro/Zepbound) additionally activates GIP receptors, producing stronger appetite suppression and weight loss than GLP-1 alone in head-to-head trials.

In separate Phase 3 trials, Zepbound (tirzepatide 15mg) produced ~20% mean body weight loss vs Wegovy (semaglutide 2.4mg) at ~15%. A head-to-head trial (SURMOUNT-5) confirmed Zepbound's edge. That said, individual response varies widely: some patients lose more on semaglutide than tirzepatide, others tolerate one's side-effect profile better than the other. Cost, insurance formulary, and dose-titration tolerability often decide which drug a patient ends up on. Both are administered as once-weekly subcutaneous injections with similar titration schedules.